Featured
December 1, 2025
Researchers have reached a major milestone in the effort to understand and treat Parkinson’s disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson’s Genetics Program (GP2).
Read More
On genomics podcast Mendelspod, Andy Singleton, co-lead of the Global Parkinson's Genetics Program (GP2), and Nacho Mata, Cleveland Clinic geneticist and LARGE-PD founder, discuss how GP2 is accelerating discovery and expanding global representation in Parkinson’s research.
View Story
Reports that the College of Medicine, University of Lagos (CMUL) commissioned the GP2–CMUL Molecular Laboratory to strengthen Parkinson’s disease research, genomics capacity, and training opportunities across Africa in collaboration with Aligning Science Across Parkinson’s (ASAP) and the Global Parkinson’s Genetics Program (GP2).
Read More
We are proud to share how we impacted the Parkinson’s disease research field in 2025. Read our report to see how the infrastructure and processes we established are changing the way science is done and are generating significant momentum.
Read More
Researchers have reached a major milestone in the effort to understand and treat Parkinson’s disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson’s Genetics Program (GP2).
Read More
GP2 announced its 11th data release at the end of 2025, bringing the total to over 100,000 samples from individuals worldwide, making it one of the most comprehensive and globally representative PD datasets to date.
Read More
In this second edition of the ASAP Research Round-Up, ASAP shares advancements in Q2 2025 across the ASAP portfolio that fill critical knowledge gaps, promote rapid dissemination of scientific insights, expand resource accessibility, and support the next generation of Parkinson’s researchers.
Read More
This news story reports on a new, advanced imaging method that allowed CRN Team Wood to see and study the tiny, toxic alpha-synuclein oligomers (protein clumps) in the brain, creating a new opportunity for earlier diagnosis and better drug treatments.
View Story
ASAP’s Sonya Dumanis, PhD, and Andrew Singleton, PhD, joined The Genetics Podcast to discuss their recent publication in the American Journal of Human Genetics. In the episode, they emphasize the importance of increasing genetic diversity in Parkinson’s disease research and highlight GP2’s role in creating a scalable roadmap for building global research collaborations that can be adapted to other diseases and regions.
View Story
In this second edition of the ASAP Research Round-Up, ASAP shares advancements in Q2 2025 across the ASAP portfolio that fill critical knowledge gaps, promote rapid dissemination of scientific insights, expand resource accessibility, and support the next generation of Parkinson’s researchers.
Read More
